

Systemic chemotherapy with or without cetuximab in p  
liver metastasis (New EPOC): long-term results of a mul  
phase 3 trial

Lancet Oncology, The  
21, 398-411

DOI: [10.1016/s1470-2045\(19\)30798-3](https://doi.org/10.1016/s1470-2045(19)30798-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	ASO Author Reflections: The Landmark Series: Randomized Control Trials Examining Perioperative Chemotherapy and Postoperative Adjuvant Chemotherapy for Resectable Colorectal Liver Metastasis. <i>Annals of Surgical Oncology</i> , 2020, 27, 4271-4272.	1.5	0
3	Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer. <i>Cancers</i> , 2020, 12, 3535.	3.7	10
4	The Landmark Series: Randomized Control Trials Examining Perioperative Chemotherapy and Postoperative Adjuvant Chemotherapy for Resectable Colorectal Liver Metastasis. <i>Annals of Surgical Oncology</i> , 2020, 27, 4263-4270.	1.5	24
5	Molecular Targets for the Treatment of Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 2350.	3.7	30
6	Chemotherapy in combination with resection for colorectal liver metastases – current evidence. <i>Surgery in Practice and Science</i> , 2020, 3, 100021.	0.4	2
7	Comment on Chun et al, “A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases”. <i>Clinical Colorectal Cancer</i> , 2020, 19, e262-e263.	2.3	1
8	Hepatic metastases resection after cetuximab: are we missing something?. <i>Lancet Oncology</i> , The, 2020, 21, e228.	10.7	1
9	Hepatic metastases resection after cetuximab: are we missing something? – Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e229.	10.7	1
10	Perioperative cetuximab plus chemotherapy reduces overall survival in metastatic disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 194-194.	17.8	0
11	EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit?. <i>Lancet Oncology</i> , The, 2020, 21, 324-326.	10.7	7
12	Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer. <i>International Cancer Conference Journal</i> , 2021, 10, 87-90.	0.5	1
13	What is the Best Therapeutic Strategy for Metachronous Resectable Colorectal Liver Metastases After Adjuvant Oxaliplatin-Based Chemotherapy? A Multidisciplinary Inter-Group Survey. <i>World Journal of Surgery</i> , 2021, 45, 822-830.	1.6	3
14	Surgical Management of Colorectal Cancer Liver Metastases. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 1-25.	1.5	15
15	Neuroendocrine Carcinoma of the Anus and Rectum: Patient Characteristics and Treatment Options. <i>Clinical Colorectal Cancer</i> , 2021, 20, e139-e149.	2.3	5
16	Narrative review of the role of yttrium-90 selective internal radiation therapy in the surgical management of colorectal liver metastases. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2438-2446.	1.4	1
17	New Molecular Targeted Therapy of Metastatic Colorectal Cancer. <i>The Ewha Medical Journal</i> , 2021, 44, 11-18.	0.2	1
18	We Need More Data: Choosing the Optimal Treatment Strategy for Patients with Resectable Metachronous Resectable Colorectal Liver Metastases. <i>World Journal of Surgery</i> , 2021, 45, 831-832.	1.6	0
20	Survival benefit of neoadjuvant chemotherapy and surgery versus surgery first for resectable colorectal liver metastases: a cohort study. <i>ANZ Journal of Surgery</i> , 2021, 91, 1196-1202.	0.7	5

#	ARTICLE	IF	CITATIONS
21	Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. <i>European Radiology</i> , 2021, 31, 5615-5628.	4.5	14
22	FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Left-Sided RAS / BRAF Wild-Type Colorectal Cancer: Which Side Are You On?. <i>Oncologist</i> , 2021, 26, 277-280.	3.7	1
23	Identification of key genes involved in tumor immune cell infiltration and cetuximab resistance in colorectal cancer. <i>Cancer Cell International</i> , 2021, 21, 135.	4.1	5
24	HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 638.	3.7	6
25	Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 144, 368-381.	2.8	34
26	Current Status of Biologics in Perioperative Treatment for Resectable or Borderline Resectable Liver Metastases. <i>Current Colorectal Cancer Reports</i> , 2021, 17, 10-22.	0.5	0
27	Deep Learning Automated Segmentation for Muscle and Adipose Tissue from Abdominal Computed Tomography in Polytrauma Patients. <i>Sensors</i> , 2021, 21, 2083.	3.8	20
28	Prognostic and Therapeutic Implications of Tumor Biology, Including Gene Alterations, in Colorectal Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1591-1600.	1.7	4
29	ASO Author Reflections: Disappearing Liver Metastases: Should We Be Afraid of the Dark?. <i>Annals of Surgical Oncology</i> , 2021, 28, 6814-6815.	1.5	0
30	The Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 2567-2579.	1.9	25
32	Case Report: Cetuximab in Combination With Chemotherapy for the Treatment of Multifocal Hepatic Metastases From Colorectal Cancer Guided by Genetic Tests. <i>Frontiers in Oncology</i> , 2021, 11, 612171.	2.8	2
33	Does laparoscopic resection for colorectal cancer liver metastasis have a long-term oncologic advantage?. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 246-248.	1.5	2
34	Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection. <i>Cancers</i> , 2021, 13, 2148.	3.7	8
35	Upfront chemotherapy and short-course radiotherapy with delayed surgery for locally advanced rectal cancer with synchronous liver metastases. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2814-2820.	1.0	2
36	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003620.	8.4	88
37	Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT. <i>Journal of Clinical Medicine</i> , 2021, 10, 2131.	2.4	13
38	Advances in Treatment Selection for Patients with Metastatic Colorectal Cancer. <i>Advances in Oncology</i> , 2021, 1, 297-310.	0.2	0
39	Neoadjuvant Pelvic Radiotherapy in the Management of Rectal Cancer with Synchronous Liver Metastases: Is It Worth It?. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2411-2422.	1.7	3

#	ARTICLE	IF	CITATIONS
40	DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 254.	17.1	239
41	Precision Medicine for the Treatment of Colorectal Cancer: the Evolution and Status of Molecular Profiling and Biomarkers. <i>Current Colorectal Cancer Reports</i> , 2021, 17, 55-68.	0.5	3
42	Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection ( AIO KRK 0306; FIRE â€³). <i>International Journal of Cancer</i> , 2021, 149, 1935-1943.	5.1	3
43	Colorectal Cancer, Liver Metastases and Biotherapies. <i>Biomedicines</i> , 2021, 9, 894.	3.2	5
44	Perioperative Systemic Chemotherapy for Colorectal Liver Metastasis: Recent Updates. <i>Cancers</i> , 2021, 13, 4590.	3.7	7
45	Breaking the Silence of Tumor Response: Future Prospects of Targeted Radionuclide Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, .	1.7	1
46	New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111824.	5.6	106
48	Parenchymal-sparing hepatectomy for colorectal liver metastases reduces postoperative morbidity while maintaining equivalent oncologic outcomes compared to non-parenchymal-sparing resection. <i>Surgical Oncology</i> , 2021, 38, 101631.	1.6	16
49	Neoadjuvant chemotherapy for colorectal liver metastases: A contemporary review of the literature. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1043-1061.	2.0	21
50	Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 4547.	3.7	12
51	Effect of Adding Bevacizumab to Chemotherapy on Pathologic Response to Preoperative Systemic Therapy for Resectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis. <i>Clinical Colorectal Cancer</i> , 2021, 20, 265-272.	2.3	7
52	Prognostic impact of neoadjuvant chemotherapy in patients with synchronous colorectal liver metastasis: A propensity score matching comparative study. <i>International Journal of Surgery</i> , 2021, 94, 106106.	2.7	4
53	Adjuvant oxaliplatin-based chemotherapy effect after treatment of colorectal hepatic metastasis. <i>Annals of Surgical Treatment and Research</i> , 2021, 101, 160.	1.0	1
54	Debate. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 205-218.	1.5	6
55	Mediation of Tumor Cell Death by Naked Antibodies. , 2021, , 57-77.		0
56	Practical recommendation for treatment of patients with colon cancer during covid-19 pandemic. <i>Meditinskiy Sovet</i> , 2020, , 213-224.	0.5	1
57	Canadian Guidelines on the Management of Colorectal Peritoneal Metastases. <i>Current Oncology</i> , 2020, 27, 621-631.	2.2	6
58	Simultaneous colorectal and parenchymal-sparing liver resection for advanced colorectal carcinoma with synchronous liver metastases: Between conventional and mini-invasive approaches. <i>World Journal of Gastroenterology</i> , 2020, 26, 6529-6555.	3.3	4

#	ARTICLE	IF	CITATIONS
59	Mutant KRAS as a prognostic biomarker after hepatectomy for rectal cancer metastases: Does the primary disease site matter?. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2022, 29, 417-427.	2.6	5
60	Development and Validation of a Novel Serum Prognostic Marker for Patients with Metastatic Colorectal Cancer on Regorafenib Treatment. <i>Cancers</i> , 2021, 13, 5080.	3.7	8
61	New Insights on the Treatment of Colorectal Peritoneal Metastases From the CAIRO6 Trial—Reply. <i>JAMA Surgery</i> , 2022, 157, 171.	4.3	1
62	Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. <i>Science Advances</i> , 2021, 7, eabi7511.	10.3	23
63	Metastatic Rectal Carcinoma with Long-Term Remission due to Modern Multimodality Treatment. <i>Case Reports in Oncology</i> , 2021, 14, 1475-1482.	0.7	1
64	Defining Early Multidisciplinary Goals: NEXTO Trial in High-Risk Colorectal Cancer with Liver Metastases. <i>Annals of Surgical Oncology</i> , 2020, 27, 4075-4078.	1.5	0
65	The Contemporary Role of Resection and Ablation in Colorectal Cancer Liver Metastases. <i>Digestive Disease Interventions</i> , 2020, 04, 291-302.	0.2	0
66	Tailored Systemic Therapy for Colorectal Cancer Liver Metastases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11780.	4.1	7
67	DIAGNOSTICS, TREATMENT AND PROGNOSIS IN PATIENTS WITH COLORECTAL CANCER AND PERITONEAL CARCINOMATOSIS (review). <i>Koloproktologia</i> , 2020, 19, 131-149.	0.6	2
68	The actual management of colorectal liver metastases. <i>Minerva Chirurgica</i> , 2020, 75, 328-344.	0.8	0
69	Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. <i>Current Oncology</i> , 2021, 28, 4894-4928.	2.2	0
70	Aspartate Aminotransferase-to-Platelet Ratio Index Predicts Liver Failure After Resection of Colorectal Liver Metastases. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4950-4958.	2.3	2
71	Shifting concepts in the management of colorectal liver metastases. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2022, . .	1.8	2
72	Chemotherapy in resectable or potentially resectable colon cancer with liver metastases. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 663-672.	1.8	3
73	A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 1345-1356.	1.9	3
74	Resource Oriented Decision Making for Treatment of Metastatic Colorectal Cancer (mCRC) in a Lower-Middle Income Country: Egyptian Foundation of Medical Sciences (EFMS) Consensus Recommendations 2020. <i>Cancer Management and Research</i> , 2022, Volume 14, 821-842.	1.9	2
75	Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial). <i>Cancers</i> , 2022, 14, 1183.	3.7	1
76	MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer. <i>Cell Death and Disease</i> , 2022, 13, 256.	6.3	4

#	ARTICLE	IF	CITATIONS
77	Associating liver partition and portal vein ligation for staged hepatectomy procedure versus conventional two-stage hepatectomy for colorectal liver metastasis. The Cochrane Library, 2022, 2022, .	2.8	0
78	Colorectal liver metastasis: molecular mechanism and interventional therapy. Signal Transduction and Targeted Therapy, 2022, 7, 70.	17.1	88
79	A Tumor Microenvironmentsâ€Adapted Polypeptide Hydrogel/Nanogel Composite Boosts Antitumor Molecularly Targeted Inhibition and Immunoactivation. Advanced Materials, 2022, 34, e2200449.	21.0	61
80	Colorectal liver metastases: state-of-the-art management and surgical approaches. Langenbeck's Archives of Surgery, 2022, 407, 1765-1778.	1.9	7
81	Targeted Therapy for Colorectal Cancer. Surgical Oncology Clinics of North America, 2022, 31, 255-264.	1.5	19
82	The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features. Cancer Treatment Reviews, 2022, 106, 102382.	7.7	9
83	Liver regeneration biology: Implications for liver tumour therapies. World Journal of Clinical Oncology, 2021, 12, 1101-1156.	2.3	5
84	Comprehensive Imaging Characterization of Colorectal Liver Metastases. Frontiers in Oncology, 2021, 11, 730854.	2.8	7
85	Time to halt perioperative chemotherapy for resectable colorectal liver metastasis?. British Journal of Surgery, 2022, 109, 242-243.	0.3	5
86	Analysis of Hepatic Artery Infusion (HAI) Chemotherapy Using Randomized Trials of Floxuridine (FUDR) for Colon Cancer Patients with Multiple Liver Metastases. Gastroenterology Research and Practice, 2022, 2022, 1-8.	1.5	3
87	Repeat Resection for Advanced Colorectal Liver Metastasesâ€Does it have the Potential for Cure?. World Journal of Surgery, 2022, 46, 2253-2261.	1.6	0
88	Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization. Clinical Imaging, 2022, 89, 112-119.	1.5	1
89	Role of Neoadjuvant therapy in the treatment of patients with colorectal liver metastases. , 2023, , 81-99.		0
90	Use of molecular markers and other personalized factors in treatment decisions for metastatic colorectal cancer. , 2023, , 65-80.		0
91	Immunotherapy and targeted therapies for colorectal liver metastasis. , 2023, , 231-246.		0
92	Monoclonal Antibodies for First-Line Treatment Metastatic Colorectal Cancer. American Journal of Therapeutics, 0, Publish Ahead of Print, .	0.9	0
93	Microsatellite instability is associated with worse overall survival in resectable colorectal liver metastases. American Journal of Surgery, 2022, , .	1.8	2
94	Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer: Lessons Learned and Future Perspectives. Current Treatment Options in Oncology, 2022, 23, 1320-1337.	3.0	7

#	ARTICLE	IF	CITATIONS
95	Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211117.	3.2	8
96	Simultaneous resection of synchronous colorectal liver metastasis: Feasibility and development of a prediction model. Annals of Hepato-biliary-pancreatic Surgery, 2023, 27, 40-48.	0.1	6
97	Oncologic aspects of the decision-making process for surgical approach for colorectal liver metastases progressing during chemotherapy. World Journal of Gastrointestinal Surgery, 0, 14, 877-886.	1.5	0
98	Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis. Cancers, 2022, 14, 4340.	3.7	1
99	Neoadjuvant chemotherapy improves overall survival in resectable colorectal liver metastases patients with high clinical risk scores – A retrospective, propensity score matching analysis. Frontiers in Oncology, 0, 12, .	2.8	3
100	The Role of Systemic Therapy in Resectable Colorectal Liver Metastases: Systematic Review and Network Meta-Analysis. Oncologist, 2022, 27, 1034-1040.	3.7	6
101	Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2023, 34, 10-32.	1.2	316
102	Colorectal Cancer Liver Metastases. Surgical Oncology Clinics of North America, 2023, 32, 119-141.	1.5	7
103	PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer. British Journal of Cancer, 2023, 128, 245-254.	6.4	2
104	Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study. Cancers, 2022, 14, 5513.	3.7	3
105	Targeted Therapy with Anti-EGFR and Anti-VEGF Therapy and Beyond. , 2022, , 293-299.		0
106	Histopathological Patterns of Progression and Vessel Co-option. , 2022, , 447-450.		0
107	Resection Margins. , 2022, , 155-162.		0
108	Improved Survival After CLM Resection over 20 Years. , 2022, , 537-548.		0
109	Initial Systemic Chemotherapy for Metastatic Colorectal Cancer. , 2022, , 279-286.		0
110	Perioperative Chemotherapy: Review of Randomized Trials and Recommended Approach. , 2022, , 197-209.		0
111	Adjuvant Systemic Chemotherapy. , 2022, , 301-308.		0
112	Chemosaturation for primary and secondary liver malignancies: A comprehensive update of current evidence. Cancer Treatment Reviews, 2023, 113, 102501.	7.7	3

#	ARTICLE	IF	CITATIONS
113	Circulating Tumor DNA: Towards More Individualized Treatment for Patients with Resectable Colorectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 1071-1081.	1.3	2
114	The Impact of Molecular Biology in the Seeding, Treatment Choices and Follow-Up of Colorectal Cancer Liver Metastases—A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1127.	4.1	2
115	Total Neoadjuvant Chemotherapy in Rectal Cancer: Current Facts and Future Strategies. <i>Journal of the Anus, Rectum and Colon</i> , 2023, 7, 1-7.	1.1	1
116	Posthepatectomy but not prehepatectomy chemotherapy was associated with a longer time to recurrence in patients with resectable colorectal liver metastases: Inverse probability of treatment weighting analysis. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 0, , .	2.6	0
117	Liver transplantation for isolated unresectable colorectal liver metastases - Protocol for a service evaluation in the United Kingdom - UKCoMET study. <i>Hpb</i> , 2023, 25, 684-692.	0.3	1
118	CACA guidelines for holistic integrative management of rectal cancer. , 2023, 2, .		0
119	Systemic treatment for metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 0, 29, 1425-1444.	3.3	0
120	Systemic treatment for metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 0, 29, 1569-1588.	3.3	8
121	Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 1271.	7.4	42
122	Survival outcomes for patients with colorectal cancer with synchronous liver only metastasis. <i>ANZ Journal of Surgery</i> , 0, , .	0.7	2
123	Targeted therapy. , 2023, , 413-458.		0
124	Lipid Nanoparticles-Based Therapy in Liver Metastasis Management: From Tumor Cell-Directed Strategy to Liver Microenvironment-Directed Strategy. <i>International Journal of Nanomedicine</i> , 0, Volume 18, 2939-2954.	6.7	1
125	Neoadjuvant chemotherapy versus upfront surgery as the initial treatment for patients with resectable, synchronous colorectal cancer liver metastases. <i>Journal of Surgical Oncology</i> , 0, , .	1.7	0
126	Platycodin D represses $\beta$ -catenin to suppress metastasis of cetuximab-treated <i>KRAS</i> wild-type colorectal cancer cells. <i>Clinical and Experimental Metastasis</i> , 0, , .	3.3	0
127	The genomics of liver metastases from colon and rectal cancer: An Invited Commentary (invitation) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 and Secondary Liver Malignancies—Surgery, 2023, 174, 422-424.	1.9	0
128	$\beta$ T cell dichotomy with opposing cytotoxic and wound healing functions in human solid tumors. <i>Nature Cancer</i> , 2023, 4, 1122-1137.	13.2	8
129	Objective Definition and Optimized Strategy for “Biologically Borderline Resectable” Colorectal Liver Metastases. <i>World Journal of Surgery</i> , 2023, 47, 2834-2845.	1.6	1
130	LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type <i>RAS</i> , potentially resectable colorectal cancer liver metastases—a phase II study. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0



#	ARTICLE	IF	CITATIONS
131	Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy. <i>Gut</i> , 0, , gutjnl-2023-330748.	12.1	2
132	Integrated Clinical-Molecular Classification of Colorectal Liver Metastases. <i>JAMA Oncology</i> , 2023, 9, 1245.	7.1	7
133	Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs. <i>Drug Resistance Updates</i> , 2023, 71, 101002.	14.4	6
134	Perioperative Chemotherapy is Associated with Superior Overall Survival in Patients with Synchronous Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 0, , .	1.5	1
135	The efficacy and safety of anti-EGFR target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trials. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	1.9	0
136	Quenching thirst with poison? Paradoxical effect of anticancer drugs. <i>Pharmacological Research</i> , 2023, 198, 106987.	7.1	0
137	Total neoadjuvant therapy in rectal cancer: the evidence and expectations. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 192, 104196.	4.4	1
138	Selecting Optimal First-Line Treatment for Microsatellite Stable and Non-Mutated RAS/BRAF Metastatic Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 0, , .	3.0	0
140	Recurrence Patterns and Risk Factors after Curative Resection for Colorectal Cancer: Insights for Postoperative Surveillance Strategies. <i>Cancers</i> , 2023, 15, 5791.	3.7	0
141	Optimizing Treatment Strategy for Oligometastases/Oligo-Recurrence of Colorectal Cancer. <i>Cancers</i> , 2024, 16, 142.	3.7	0
142	Nontumor Cells in Tumor Samples Bias Expression-Based Models—Reply. <i>JAMA Oncology</i> , 2024, 10, 260.	7.1	0
143	Feasibility of Hepatic Artery Infusion Chemotherapy for Colorectal Liver Metastasis in an Indian Setting. <i>Indian Journal of Surgical Oncology</i> , 0, , .	0.7	0
145	Multimodal Management of Colorectal Liver Metastases: State of the Art. <i>Oncology Reviews</i> , 0, 17, .	1.8	0
146	Improved survival of patients receiving immunotherapy and chemotherapy following curative-intent resection of colorectal liver metastases. <i>Journal of Gastrointestinal Surgery</i> , 2024, 28, 246-251.	1.7	0
147	Pan-European survey on current treatment strategies in patients with upfront resectable colorectal liver metastases. <i>Hpb</i> , 2024, 26, 639-647.	0.3	0
148	Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer. <i>Cells</i> , 2024, 13, 245.	4.1	1
149	Preoperative chemotherapy in upfront resectable colorectal liver metastases: New elements for an old dilemma?. <i>Cancer Treatment Reviews</i> , 2024, 124, 102696.	7.7	0
150	Current landscape of preoperative neoadjuvant therapies for initial resectable colorectal cancer liver metastasis. <i>World Journal of Gastroenterology</i> , 0, 30, 663-672.	3.3	0

#	ARTICLE	IF	CITATIONS
151	Contemporary Surgical Management of Colorectal Liver Metastases. <i>Cancers</i> , 2024, 16, 941.	3.7	0
152	Tata Memorial Centre Evidence Based Management of Colorectal cancer. <i>Indian Journal of Cancer</i> , 2024, 61, S29-S51.	0.2	0